Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 14/20 | 0.49 |
| ▸ | F13A1 | P00488 | 11/20 | 0.49 |
| ▸ | TGM1 | P22735 | 8/20 | 0.49 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | DTYMK | P23919 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13239816 | 0.83 | TGM2 (0.59) | TGM2F13A1TGM1TGM3GPR119 | |
| SCHEMBL1180627 | 0.82 | TGM2 (0.60) | TGM2F13A1TGM1TGM3ALDH1A1 | |
| SCHEMBL5262401 | 0.82 | TGM2 (0.51) | TGM2F13A1TGM1TGM3GPR119 | |
| SCHEMBL2252120 | 0.80 | TGM2 (0.63) | TGM2F13A1TGM1GPR119ALDH1A1 | |
| SCHEMBL4266289 | 0.80 | CNR1 (0.59) | TGM2F13A1TGM1TGM3ALDH1A1 | |
| SCHEMBL5259618 | 0.80 | TGM2 (0.52) | TGM2F13A1TGM1TGM3GPR119 | |
| SCHEMBL14672159 | 0.79 | GPR119 (0.50) | GPR119ALDH1A1SMN1; SMN2LMNAGAA | |
| SCHEMBL3248533 | 0.79 | TGM2 (0.55) | TGM2F13A1TGM1TGM3LMNA | |
| SCHEMBL18229990 | 0.78 | PKM (0.62) | ALDH1A1LMNAGAA | |
| SCHEMBL14266676 | 0.77 | KMT2A (0.46) | ALDH1A1TSHRSMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118718-A1 | Substituted Quinoxaline Derivatives | SELVITA S.A. (PL) | 2018-05-03 | — | — | US | disclosed |
| US-20180118718-A1 | Substituted Quinoxaline Derivatives | SELVITA S.A. (PL) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118718-A1 | Substituted Quinoxaline Derivatives | BRCA1, NQO2, NQO1 | TGM2 1616/4885F13A1 4557/4885TGM1 1103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.